当前位置: X-MOL 学术Eur. J. Cell Biol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising frontier.
European Journal of Cell Biology ( IF 6.6 ) Pub Date : 2020-06-26 , DOI: 10.1016/j.ejcb.2020.151097
Ali Shariati 1 , Reza Nemati 2 , Yasin Sadeghipour 3 , Yoda Yaghoubi 4 , Reza Baghbani 2 , Kamran Javidi 5 , Majid Zamani 6 , Ali Hassanzadeh 7
Affiliation  

Neurodegenerative disorders are a variety of diseases including Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) along with some other less common diseases generally described by the advanced deterioration of central or peripheral nervous system, structurally or functionally. In the last two decades, mesenchymal stromal cells (MSCs) due to their unique assets encompassing self-renewal, multipotency and accessibility in association with low ethical concern open new frontiers in the context of neurodegenerative diseases therapy. Interestingly, MSCs can be differentiated into endodermal and ectodermal lineages (e.g., neurons, oligodendrocyte, and astrocyte), and thus could be employed to advance cell-based therapeutic strategy. Additionally, as inflammation ordinarily ensues as a local response provoked by microglia in the neurodegenerative diseases, MSCs therapy because of their pronounced immunomodulatory properties is noticed as a rational approach for their treatment. Recently, varied types of studies have been mostly carried out in vitro and rodent models using MSCs upon their procurement from various sources and expansion. The promising results of the studies in rodent models have motivated researchers to design and perform several clinical trials, with a speedily rising number. In the current review, we aim to deliver a brief overview of MSCs sources, expansion strategies, and their immunosuppressive characteristics and discuss credible functional mechanisms exerted by MSCs to treat neurodegenerative disorders, covering AD, PD, ALS, MS, and HD.



中文翻译:

用于神经退行性疾病的间充质基质细胞(MSC):一个有前途的前沿。

神经退行性疾病是多种疾病,包括阿尔茨海默氏病(AD),帕金森氏病(PD)和亨廷顿氏病(HD),多发性硬化症(MS)和肌萎缩性侧索硬化症(ALS)以及其他一些较不常见的疾病,通常以晚期恶化为特征中枢或周围神经系统的结构或功能。在过去的二十年中,间充质基质细胞(MSCs)由于其独特的资产包括自我更新,多能性和可及性以及低伦理关注度,在神经退行性疾病治疗的背景下开辟了新的领域。有趣的是,MSC可以分化为内胚层和外胚层谱系(例如神经元,少突胶质细胞和星形胶质细胞),因此可以用于推进基于细胞的治疗策略。另外,由于炎症通常是神经退行性疾病中由小胶质细胞引起的局部反应,因此,MSCs的治疗由于其明显的免疫调节特性而被认为是治疗的合理方法。近来,在从各种来源获得并扩展了MSC的情况下,已经使用MSC进行了各种类型的研究,其中大多数是在体外和啮齿动物模型上进行的。啮齿动物模型研究的有希望的结果激励了研究人员设计和进行多项临床试验,并且数量迅速增加。在当前的审查中,我们旨在简要概述MSC的来源,扩展策略及其免疫抑制特性,并讨论MSC发挥可靠的功能机制来治疗神经退行性疾病,涵盖AD,PD,ALS,MS和HD。

更新日期:2020-06-30
down
wechat
bug